Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tōon
Clinical trial register · Japan

Clinical Trials in Tōon, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC22 NRG Oncology3 National Cancer Institute (NCI)3 Novartis Pharmaceuticals2 Bristol-Myers Squibb2
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Tōon

47 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Oslo University Hospital
Observational
400
Nagoya, Tōon
2026-09
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
150
Tōon, Bunkyō City
2026-06-02
Recruiting
Juntendo University
Phase 4
550
Handa, Nagoya, Ōbu, Toyota, Tōon, Fukuoka, Iizuka, Maebashi
2026-05-11
Recruiting
Mirati Therapeutics Inc.
Phase 2
170
Tōon
2026-05-06
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
Nagoya, Hirosaki, Tōon, Sapporo, Kobe, Tsukuba, Kita-gun, Kawasaki
2026-04-23
Recruiting
Bristol-Myers Squibb
Phase 3
750
Toyohashi, Funabashi, Tōon, Sapporo, Nishinomiya, Kanazawa, Kamakura, Yokohama
2026-03-12
Recruiting
Regeneron Pharmaceuticals
Phase 3
1,120
Tōon, Akashi, Kita-gun, Isehara-Shi, Kyoto, Chuo, Ina-machi, Shinjuku
2026-03-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Nagoya, Tōon, Kurume, Ōta, Sapporo, Akashi, Shiwa-gun, Yokohama
2026-01-19
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Nagoya, Kashiwa, Tōon, Kurume, Sapporo, Nishinomiya, Yokohama, Sendai
2025-11-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Nagoya, Toyoake, Hirosaki, Tōon, Kurume, Ōta, Himeji, Kobe
2025-10-08
Recruiting
Chugai Pharmaceutical
Phase 1
122
Kashiwa, Tōon, Sakai, Niigata
2025-10-08
Recruiting
Pfizer
Phase 3
714
Tōon, Kurume, Otashi, Asahikawa, Kobe, Yokohama, Tsu, Sendai
2025-07-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Nagoya, Matsuyama, Tōon, Kurume, Ōta, Sapporo, Akashi, Shiwa-gun
2025-05-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Nagoya, Sakura, Tōon, Kitakyushu, Kurume, Sapporo, Kobe, Kahoku-gun
2025-05-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Ōta, Sapporo, Shiwa-gun
2025-04-09
Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, FIGO Stage III Ovarian Cancer 2014
DrugsIBI305·HD204·Bevacizumab-awwb·BP102
NRG Oncology
Phase 3
880
Sendai, Tōon, Kure, Sapporo, Akashi, Shiwa-gun, Kagoshima, Gunma
2025-03-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Toyoake, Tōon, Kitakyushu, Takarazuka, Yokohama, Nankoku, Natori-shi, Sakai
2024-11-21
Recruiting
Prevail Therapeutics
Phase 1
124
Tōon, Yufu, Hachiōji
2024-08-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
686
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Ohta, Sapporo, Tsukuba
2024-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Toyoake, Tōon, Sapporo, Kobe, Kanazawa, Tsu, Sendai, Hirakata
2024-07-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Toyoake, Tōon, Fukuoka, Ōta, Kanazawa, Kawasaki, Yokohama, Natori-shi
2024-06-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Nagoya, Toyoake, Hirosaki, Kashiwa, Tōon, Ōta, Kobe, Takarazuka
2024-06-10
Active, closed
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
DrugAdagrasib
Mirati Therapeutics Inc.
Phase 2
200
Tōon, Nishinomiya, Kashiwa, Osaka
2024-02-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Sakura, Tōon, Kitakyushu, Kurume, Asahikawa, Sapporo, Kobe, Mukai-awagasaki
2023-12-31
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Toyoake, Kashiwa, Tōon, Sapporo, Kobe, Kanazawa, Tsu, Sendai
2023-12-31
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Nagoya, Matsuyama, Tōon, Kurume, Otashi, Sapporo, Tsukuba, Shiwa-gun
2023-12-06
Recruiting
NRG Oncology
Phase 3
3,960
Tōon, Sapporo, Akashi, Gunma, Koto-ku, Hiroshima, Kyoto, Matsuyama
2023-10-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Toyoake, Kashiwa, Sakura, Tōon, Sapporo, Yokohama, Kashihara, Sakai
2022-03-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Kashiwa, Matsuyama, Tōon, Kurume, Otashi, Sapporo, Tsukuba, Shiwa-gun Yahaba-cho
2022-02-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
643
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Sapporo, Shiwa-gun Yahaba-cho, Kawasaki
2021-12-13
Recruiting
NRG Oncology
Phase 3
1,670
Tōon, Sapporo, Akashi, Gunma, Koto-ku, Hiroshima, Kyoto, Matsuyama
2021-06-23
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Toyoake, Kashiwa, Tōon, Sapporo, Yokohama, Kashihara, Sayama, Suita
2021-04-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Ōta, Sapporo, Akashi
2021-01-10
Active, closed
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT04452591Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
DrugCretostimogene Grenadenorepvec
CG Oncology, Inc.
Phase 3
190
Kashiwa-shi, Tōon, Sapporo, Kandori, Marugame, Kawasaki, Yokohama, Kyoto
2020-10-27
Active, closed
PharmaEssentia
Phase 3
174
Tōon, Sagamihara, Tsu, Miyazaki, Hirakata, Sayama, Suita, Izunokuni
2020-08-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
755
Toyoake, Kashiwa, Tōon, Sapporo, Yokohama, Kashihara, Sayama, Suita
2020-02-27
Active, closed
Pfizer
Phase 3
1,068
Matsuyama, Tōon, Fukuoka, Ōta, Sapporo, Yokohama, Osaka, Sakai
2019-12-30
Recruiting
Study of Out of Specification for Tisagenlecleucel
NCT04094311B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
DrugTisagenlecleucel
Novartis Pharmaceuticals
Phase 3
200
Nagoya, Tōon, Gifu, Sapporo, Kobe, Nishinomiya, Tsukuba, Kita-gun
2019-11-21
Active, closed
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
DrugsParaplatin·Taxol·Keytruda·Paclitaxel
National Cancer Institute (NCI)
Phase 3
813
Tōon, Kure, Niigata, Saitama
2019-08-22
Active, closed
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
DrugsCis-platinum·CDDP·Tecentriq·Paraplatin
National Cancer Institute (NCI)
Phase 3
544
Sendai, Tōon, Sapporo, Kagoshima, Gunma, Niigata, Mitaka-shi, Hiroshima
2019-07-26
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Tōon, Sapporo, Shiwa-Gun, Sendai, Kawagoe, Kodaira, Shinjuku-ku, Chiba
2018-12-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Hirosaki, Tōon, Tsukuba, Kawasaki, Sagamihara, Yokosuka, Kashihara, Hamamatsu
2018-12-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Sapporo, Akashi, Himeji
2018-08-21
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugPacritinib
Swedish Orphan Biovitrum
Phase 3
407
Chūō, Fukuoka, Fukushima, Miyagi, Miyazaki, Tokyo, Tōon, Tsu
2017-06-26
Recruiting
Turning Point Therapeutics, Inc.
Phase 1/2
500
Tōon, Sapporo, Yokohama, Osaka, Chuo-ku, Yonago, Kashiwa, Nagoya
2017-03-07
Active, closed
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
DrugsCediranib Maleate·Pegylated liposomal doxorubicin·Topotecan·Taxol
National Cancer Institute (NCI)
Phase 2/3
582
Tōon, Sapporo, Kagoshima, Koto-ku, Osaka, Saitama, Tokyo
2016-05-03
Active, closed
Eli Lilly and Company
Phase 3
545
Nagoya, Kashiwa, Tōon, Kurume, Asahikawa, Akashi, Amagashiki, Himeji
2015-05-06
Rows per page Showing 1–47 of 47
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/t-on

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 47 of those studies with a site in Tōon.

How many clinical trials are recruiting in Tōon?

24 of the 47 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 23 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tōon), 47 studies
PhaseStudiesRecruitingShare
Phase 3381780.9%
Phase 1224.3%
Phase 2214.3%
Phase 2/3214.3%
Observational112.1%
Phase 1/2112.1%
Phase 4112.1%

Most active sponsors

Lead sponsors with the most studies (Tōon)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC229
National Cancer Institute (NCI)30
NRG Oncology33
Bristol-Myers Squibb22
Mirati Therapeutics Inc.21
Novartis Pharmaceuticals21
Pfizer21
CG Oncology, Inc.10
Chugai Pharmaceutical11
Dompé Farmaceutici S.p.A11
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.